【孟加拉乐伐替尼治疗肝癌效果好 索拉非尼耐药后选择乐伐替尼】<p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">服用孟加拉乐伐替尼可以活多久</font><font face="宋体"> 孟加拉乐伐替尼适合穷人用的抗癌药</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">人们常以</font><font face="宋体">“心肝宝贝”来表达某人在心里的位置，这个比喻恰到好处，要知道肝脏是我们人体中一个非常的器官。脂肪、糖类、蛋白质的新陈代谢都离不开肝脏。除此之外，肝脏还是人体一般大的解毒器官，体内产生的毒物、废物，吃进去的有害物、有损肝脏的药物都必须依靠肝脏解毒。</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">正是这么的一个器官，所背负的也很重，以至于各种疾病登门拜访，病毒性肝炎、脂肪肝、酒精肝、肝硬化、肝癌</font><font face="宋体">……</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:12.0000pt;
mso-font-kerning:0.0000pt;"></span></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"><font face="宋体">可快递代收</font> <font face="宋体">见货付款</font></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"> </span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"> <font face="宋体">相信我们，让你放心</font></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"></span></b></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"><font face="宋体">微：</font></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:Calibri;mso-fareast-font-family:宋体;
color:rgb(192,0,0);mso-ansi-font-weight:bold;font-size:18.0000pt;">wuqids11</span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;
mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"> <font face="宋体">电话</font> <font face="Calibri">18310839568</font></span></b><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-fareast-font-family:宋体;
color:rgb(192,0,0);font-size:18.0000pt;mso-font-kerning:0.0000pt;"></span></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">肝脏的疾病种类繁多，但一般让人揪心的要数肝癌了。肝癌对于中国人而言，可谓是一个</font><font face="宋体">“软肋”。全球近一半的肝癌患者都在中国。另外，近80%的患者确诊的时候就是中晚期，无法进行手术根治。</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">因为大部分晚期的肝癌患者无法进行手术根治，所以转而接受系统疗法是目前的主流，尤其是常伴有其他慢性肝病的中国患者，系统治疗不可或缺。</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">一般近几年，肝癌系统治疗发展迅速，多款抗癌药相继上市，也为晚期肝癌患者带来了福音。其中，仑伐替尼是近十年来肝癌一线治疗的一个突破，有效率高，还可延长中国患者的生存期。但仑伐替尼的潜在临床价值可能不止如此，仑伐替尼联合免疫</font><font face="宋体">PD-1疗法已经初现成效，屡屡展现出“1+1大于2”的惊艳疗效。</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:12.0000pt;
mso-font-kerning:0.0000pt;"></span></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"><font face="宋体">可快递代收</font> <font face="宋体">见货付款</font></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"> </span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"> <font face="宋体">相信我们，让你放心</font></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"></span></b></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"><font face="宋体">微：</font></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:Calibri;mso-fareast-font-family:宋体;
color:rgb(192,0,0);mso-ansi-font-weight:bold;font-size:18.0000pt;">wuqids11</span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;
mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri;color:rgb(192,0,0);
mso-ansi-font-weight:bold;font-size:18.0000pt;"> <font face="宋体">电话</font> <font face="Calibri">18310839568</font></span></b><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-fareast-font-family:宋体;
color:rgb(192,0,0);font-size:18.0000pt;mso-font-kerning:0.0000pt;"></span></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><i><span class="15" style="mso-spacerun:'yes';font-family:宋体;color:rgb(0,110,166);
letter-spacing:1.5000pt;mso-ansi-font-style:italic;font-size:14.0000pt;"><font face="宋体">1</font></span></i><b><span class="16" style="mso-spacerun:'yes';font-family:微软雅黑;color:rgb(0,110,166);
letter-spacing:1.5000pt;mso-ansi-font-weight:bold;font-size:14.0000pt;"><br></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(0,110,166);
letter-spacing:1.5000pt;mso-ansi-font-weight:bold;font-size:14.0000pt;"><font face="宋体">仑伐替尼一线单药表现不凡对中国肝癌患者疗效更佳</font></span></b><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">在一项仑伐替尼的全球</font><font face="宋体">III期临床研究REFLECT中, 共纳入954例未经系统治疗的不可切除的肝癌患者，1:1随机分配至仑伐替尼组和索拉非尼组。</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
mso-ansi-font-weight:bold;font-size:14.0000pt;"><font face="宋体">研究结果显示：</font></span></b><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">在总人群中仑伐替尼的客观缓解率是索拉非尼的</font><font face="宋体">3倍有余，无进展生存期较索拉非尼相比提高了1倍。</font></span><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(0,110,166);
letter-spacing:1.5000pt;mso-ansi-font-weight:bold;font-size:14.0000pt;"><font face="宋体">而在中国人群中，仑伐替尼组的中位总生存期高达</font><font face="宋体">15个月，而索拉非尼组只有10.2个月，提高了近5个月</font></span></b><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">。</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><i><span class="15" style="mso-spacerun:'yes';font-family:宋体;color:rgb(0,110,166);
letter-spacing:1.5000pt;mso-ansi-font-style:italic;font-size:14.0000pt;"><font face="宋体">2</font></span></i><b><span class="16" style="mso-spacerun:'yes';font-family:微软雅黑;color:rgb(0,110,166);
letter-spacing:1.5000pt;mso-ansi-font-weight:bold;font-size:14.0000pt;"><br></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(0,110,166);
letter-spacing:1.5000pt;mso-ansi-font-weight:bold;font-size:14.0000pt;"><font face="宋体">仑伐替尼一线助阵免疫联合疗法</font><font face="宋体">K/O皆可配</font></span></b><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">作为免疫治疗的代表，</font><font face="宋体">PD-1抗体也在肝癌二线治疗中取得不俗的战绩，一旦起效，部分患者可以长期生存。同时，大家也开始将这些药物进行联合治疗，希望可以取得1+1>2的治疗效果。这其中就有 “王炸”抗癌组合：靶向药仑伐替尼+PD-1抗体K药。</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:12.0000pt;
mso-font-kerning:0.0000pt;"></span></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;mso-ansi-font-weight:bold;
font-size:15.5000pt;"><font face="宋体">可快递代收</font><font face="宋体"> 见货付款 微：wuqids11</font></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:微软雅黑;mso-ansi-font-weight:bold;
font-size:15.5000pt;"><br></span></b><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;mso-ansi-font-weight:bold;
font-size:15.5000pt;"><font face="宋体">相信我们，让您放心</font></span></b><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:12.0000pt;
mso-font-kerning:0.0000pt;"></span></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><span style="mso-spacerun:'yes';font-family:微软雅黑;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><br></span><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">“王炸”组合一线治疗不可切除的肝癌患者的临床研究KEYNOTE-524/Study116数据，在2018年ASCO年会上，首次公布便引起国内外众多学者关注。在2019年ESMO会议上，该联合方案更新了</font></span><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
mso-ansi-font-weight:bold;font-size:14.0000pt;"><font face="宋体">临床数据</font></span></b><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">：</font></span><b><span class="16" style="mso-spacerun:'yes';font-family:宋体;color:rgb(0,110,166);
letter-spacing:1.5000pt;mso-ansi-font-weight:bold;font-size:14.0000pt;"><font face="宋体">在可评估的</font><font face="宋体">67位患者中，ORR高达44.8%，OS达到了史无前例的20.4个月，6%的患者肿瘤完全消失（CR），创下了肝癌治疗新历史</font></span></b><span style="mso-spacerun:'yes';font-family:宋体;letter-spacing:1.5000pt;
font-size:14.0000pt;mso-font-kerning:0.0000pt;"><font face="宋体">设想，仑伐替尼联合其他</font><font face="宋体">PD-1或PD-L1是否也有同样功效；或者其他的抗血管药物联合PD-1/L1是否效果依旧，我们拭目以待。我们也期待这类“免疫药物+抗血管生成药物”组合早日获批肝癌一线治疗，将肝癌治疗带入靶向联合免疫治疗的新时代，让更多肝癌患者获益。</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:12.0000pt;
mso-font-kerning:0.0000pt;"></span></p><p class="p" align="justify" style="margin-top:0.0000pt;margin-right:0.0000pt;margin-bottom:0.0000pt;
margin-left:0.0000pt;text-indent:0.0000pt;padding:0pt 0pt 0pt 0pt ;
word-break:break-all;mso-pagination:widow-orphan;text-align:justify;
text-justify:inter-ideograph;background:rgb(255,255,255);"><span style="font-family: 微软雅黑; color: rgb(51, 51, 51); letter-spacing: 1.5pt; font-size: 14pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> </span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:12.0000pt;
mso-font-kerning:0.0000pt;"></span></p><p class="p" style="margin-left:0.0000pt;text-indent:21.0000pt;word-break:break-all;
mso-pagination:widow-orphan;"><span style="mso-spacerun:'yes';font-family:Calibri;mso-fareast-font-family:微软雅黑;
font-size:10.5000pt;mso-font-kerning:0.0000pt;"> </span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:12.0000pt;
mso-font-kerning:0.0000pt;"></span></p><p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:Calibri;mso-fareast-font-family:宋体;
mso-bidi-font-family:'Times New Roman';font-size:10.5000pt;mso-font-kerning:1.0000pt;"> </span></p>
213
0
0